Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal-cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: A case report.

Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal-cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: A case report.

Introduction: Papillary renal-cell carcinoma, which represents around 20% of renal cell carcinomas, is a heterogeneous disease that includes different tumor types with several clinical and molecular phenotypes. Nivolumab, a fully human IgG4 programmed cell death protein 1 immune checkpoint inhibitor...

Full description

Bibliographic Details
Main Authors: Juan Ruiz-Bañobre, Urbano Anido, Ihab Abdulkader, José Antúnez-López, Rafael López-López, Jorge García-González
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-11-01
Series:Frontiers in Oncology
Subjects:
Immunotherapy
Renal cell carcinoma
Sunitinib
Vascular normalization
Nivolumab
Long-term response
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00250/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00250/full

Similar Items